# A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer

> **NCT05830240** · EARLY_PHASE1 · UNKNOWN · sponsor: **Shanghai Yunying Medical Technology** · enrollment: 9 (estimated)

## Conditions studied

- Head and Neck Cancer
- Esophageal Cancer
- Otorhinolaryngologic Neoplasms
- Ear Cancer
- Nose Cancer
- Laryngeal Cancer
- Pharyngeal Cancer

## Interventions

- **DRUG:** Recombinant oncolytic herpes simplex virus type 1 (R130)

## Key facts

- **NCT ID:** NCT05830240
- **Lead sponsor:** Shanghai Yunying Medical Technology
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-27
- **Primary completion:** 2025-03-27
- **Final completion:** 2026-03-27
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2023-04-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05830240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05830240, "A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05830240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*